Books+ Search Results
Unsustainable drug prices : hearing before the Committee on Oversight and Reform, House of Representatives
Title
Unsustainable drug prices : hearing before the Committee on Oversight and Reform, House of Representatives.
Publication
Washington : U.S. Government Publishing Office, 2020-2021.
Physical Description
3 volumes ; 24 cm
Notes
Shipping list no.: 2021-0089-P (pts. 1-2), 2021-0230-P (pt. 3).
"One Hundred Sixteenth Congress, second session"--Pts. 1 and 2.
"One Hundred Seventeenth Congress, first session"--Pt. 3.
"Serial no. 116-122"--Pt. 1
"Serial no. 116-123"--Pt. 2
"Serial no. 117-22"--Pt. 3
"September 30, 2020"--Pt. 1.
"October 1, 2020"--Pt. 2.
"May 18, 2021"--Pt. 3.
Date of hearing (pt. 1): 2020-09-30.
Date of hearing (pt. 2): 2020-10-01.
Variant and related titles
Title for parts I and II: Unsustainable drug prices : testimony from the CEOs
Title for part III: Unsustainable drug prices : testimony from AbbVie CEO Richard Gonzalez
Other formats
Online version: United States. Congress. House. Committee on Oversight and Reform. Unsustainable drug prices
Microfiche version: United States. Congress. House. Committee on Oversight and Reform. Unsustainable drug prices
Format
Books
Language
English
Added to Catalog
June 08, 2022
Performers
Hearing witnesses (pt. 1): Mr. Mark Alles, Former Chairman of the Board and Chief Executive Officer, Celgene Corporation; Dr. Giovanni Caforio, Chairman of the Board and Chief Executive Officer, Bristol Myers Squibb Company; Mr. Kare Schultz, President and Chief Executive Officer, Teva Pharmaceutical Industries Ltd.
Hearing witnesses (pt. 2): Mr. Robert Bradway, Chairman and Chief Executive Officer, Amgen Inc.; Mr. Mark Trudeau, President and Chief Executive Officer, Mallinckrodt Pharmaceuticals; Mr. Thomas Kendris, U.S. Country President, Novartis AG.
Subjects
Genre/Form
Legislative hearings.
Legislative hearings.
Bookmark As
Citation
